Hidradenitis Suppurativa Market Size Worth USD 1,204.7 Million in 2032 | Emergen Research

The global Hidradenitis Suppurativa (HS) market size was USD 727.4 million in 2022 and is expected to register a rapid revenue CAGR of 5.2% during the forecast period. The global market for Hidradenitis Suppurativa (HS) is experiencing notable expansion, driven by a surge in cases worldwide and heightened awareness among healthcare professionals and the public. Hidradenitis Suppurativa, a debilitating skin condition characterized by painful lumps in sweat glands, affects approximately 1-4% of the global population, predominantly women.

Key Market Drivers:

1. Increasing Research & Development (R&D) Activities: Major market players are intensifying R&D efforts, aiming to develop improved therapeutics and upgrade existing treatments. Government and non-government bodies are actively educating the populace about HS prevalence and advocating for effective treatment.

2. Significant Drug Trials: Notable advancements include FDA approvals for drugs like Cosentyx (secukinumab), marking the first new biologic treatment option for HS patients in nearly a decade. This approval underscores the pivotal role of medical technology and drug trials in shaping the future of HS treatment.

3. Rising Clinical Trials: Organizations worldwide are conducting clinical trials to assess the safety and efficacy of drugs for HS patients. Initiatives like Kymera Therapeutics' Phase 2 trial of KT-474 aim to address various aspects of HS, offering hope for improved treatment outcomes.

Get Free Sample Report and Related Graphs & Charts @https://www.emergenresearch.com/request-sample/2832

Market Restraints:

Adverse Effects of Current Therapies: Concerns about adverse effects associated with existing therapies pose a challenge to treatment adherence and patient satisfaction. This may prompt exploration of alternative therapeutic options, potentially restraining market growth.

Market Segment Insights:

Treatment Types:

Biologics Dominance: Biologics constitute the largest market share, driven by FDA approvals and increasing R&D activities. These medications offer promise in managing moderate-to-severe HS and are increasingly utilized due to their effectiveness and safety profile.

Distribution Channels:

• Hospital Pharmacies Lead: Hospital pharmacies are poised for steady growth, serving as key centers for HS diagnosis and treatment. The chronic nature of HS often necessitates specialized care, driving patients towards hospital settings.

• Online Pharmacies Rise: Online pharmacies are expected to capture a significant market share, facilitated by wide medication availability, internet penetration, and convenient home delivery options.

Request A Discount On The Report @https://www.emergenresearch.com/request-discount/2832

End-Use Insights:

Hospitals and Specialty Clinics: These segments are projected to experience moderate growth, driven by rising demand for HS treatments. Hospitals offer comprehensive care and multidisciplinary approaches essential for managing chronic conditions like HS.

The global Hidradenitis Suppurativa market presents significant growth opportunities, propelled by increased research efforts, drug innovations, and growing patient awareness. As stakeholders continue to collaborate and innovate, the market is poised for further expansion in the coming years.

Hidradenitis Suppurativa Top Companies and Competitive Landscape

The global HS market is fairly fragmented, with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective Hidradenitis Suppurativa solutions.

• Sun Pharmaceutical Industries Ltd
• Abbott
• Merck & Co., Inc.
• Novartis AG
• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Yamo Pharmaceuticals
• Hoffmann-La Roche Ltd.
• Aurobindo Pharma
• AbbVie Inc.
• Lupin
• Zydus Cadila
• Eisai Co., Ltd.
• Allergan
• Sanofi S.A
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.

Request Customization Of The Report @https://www.emergenresearch.com/request-for-customization/2832

Hidradenitis Suppurativa Latest Industry News

• On 18 July 2023, UCB, a global biopharmaceutical company, announced that the European Medicines Agency (EMA) has agreed to review the marketing authorization application for bimekizumab. Bimekizumab, an inhibitor targeting both IL-17A and IL-17F, is under consideration as a treatment for adults experiencing moderate to severe Hidradenitis Suppurativa (HS). This evaluation is supported by data derived from the Phase 3 BE HEARD I and BE HEARD II studies, as previously reported. In both trials, bimekizumab exhibited statistically significant and clinically meaningful enhancements over the placebo in signs and symptoms of Hidradenitis Suppurativa (HS) at week 16, as measured by HiSCR50.

Hidradenitis Suppurativa Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global HS market on the basis of treatment type, application, end-use, and region:

• Treatment Type Outlook (Revenue, USD Million; 2019-2032)
o Surgery
o Medications
o Biologics
o Antibiotics
o Others

• Distribution Channel Outlook (Revenue, USD Million; 2019-2032)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies

• End-Use Outlook (Revenue, USD Million; 2019-2032)
o Hospitals
o Specialty Clinics
o Homecare
o Others

• Regional Outlook (Revenue, USD Million; 2019-2032)
o North America
1. U.S.
2. Canada
3. Mexico
o Europe
1. Germany
2. France
3. UK
4. Italy
5. Spain
6. Benelux
7. Rest of Europe
o Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Rest of APAC
o Latin America
1. Brazil
2. Rest of LATAM
o Middle East & Africa
1. Saudi Arabia
2. UAE
3. South Africa
4. Turkey
5. Rest of Middle East & Africa

For more informative information, please visit us @ https://www.emergenresearch.com/industry-report/hidradenitis-suppurativa-market

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

This release was published on openPR.